title: Comparative mutagenicity testing of a drug candidate, U-48753E: mechanism of induction of gene mutations in mammalian cells and quantitation of potential hazard.
abstract: U-48753E is a potential human drug which was subjected to a battery of short-term assays for genetic activity. The compound was negative in the Salmonella (Ames) test, the in vitro UDS assay, the mouse bone-marrow micronucleus test and the Drosophila sex-linked recessive lethal assay. However, it was weakly positive in the CHO/HPRT assay in the presence of metabolic activation (S9). The weak positive response might easily have been labeled artifactual since there was no dose response and the dose level producing positive findings varied from experiment to experiment. In addition, the weak positive response was not confirmed in V79 cells. However, a reproducible dose-related increase in mutants was observed in the AS52/XPRT assay in the presence of S9. Metabolism of this drug proceeds through conversion of aliphatic N-methyl groups to formaldehyde. Addition of formaldehyde dehydrogenase to the S9 resulted in elimination of the mutagenicity of the compound in AS52 cells. Thus, the mutants were probably induced by formaldehyde. From the endogenous levels of formaldehyde in human blood, and the limiting potential therapeutic dose levels, the genotoxic hazard associated with U-48753E is marginal. This assessment of risk and its quantitation depend upon an understanding metabolism and exposure limits imposed by known side effects of the drug. This study can serve as a model for quantitative genetic risk assessment when mutagenicity is due to N-demethylation and formation of formaldehyde in situ.
authors.affiliation: Genetic Toxicology Research, Upjohn Company, Kalamazoo, MI 49001.
authors.forename: C S
authors.initials: CS
authors.lastname: Aaron
authors.forename: L F
authors.initials: LF
authors.lastname: Stankowski
authors.forename: P R
authors.initials: PR
authors.lastname: Harbach
authors.forename: R
authors.initials: R
authors.lastname: Valencia
authors.forename: J K
authors.initials: JK
authors.lastname: Mayo
authors.forename: J
authors.initials: J
authors.lastname: Mirsalis
authors.forename: J H
authors.initials: JH
authors.lastname: Mazurek
authors.forename: K L
authors.initials: KL
authors.lastname: Steinmetz
authors.forename: S K
authors.initials: SK
authors.lastname: Wiser
authors.forename: D M
authors.initials: DM
authors.lastname: Zimmer
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000493:pharmacokinetics / Q000633:toxicity*; D001711:Biotransformation; D001853:Bone Marrow / Q000187:drug effects; D002460:Cell Line; D006224:Cricetinae; D003412:Cricetulus; D003517:Cyclopentanes / Q000493:pharmacokinetics / Q000633:toxicity*; D004331:Drosophila melanogaster / Q000235:genetics; D004357:Drug Synergism; D005557:Formaldehyde / Q000097:blood / Q000494:pharmacology; D006801:Humans; D008297:Male; D015162:Micronucleus Tests; D008862:Microsomes, Liver / Q000378:metabolism; D009152:Mutagenicity Tests; D009154:Mutation; D051381:Rats; D011916:Rats, Inbred F344; D011919:Rats, Inbred Strains; D012486:Salmonella typhimurium / Q000235:genetics
chemical_list: D000928:Antidepressive Agents; D003517:Cyclopentanes; D005557:Formaldehyde; C033295:U 78753E